Positive response to imatinib mesylate therapy for childhood chronic myeloid leukemia
| Autor: | G.A.P. Oliveira, E.S. Costa, M.S. Freitas, F.F. Dutra, S.F. Maia, M.C. Guerra, M.D. Tabernero, R. Borojevic, I.B. Otazu, J.L. Silva |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2010 |
| Předmět: | |
| Zdroj: | Brazilian Journal of Medical and Biological Research, Vol 43, Iss 6, Pp 580-584 (2010) |
| Druh dokumentu: | article |
| ISSN: | 0100-879X 1414-431X |
| Popis: | Chronic myeloid leukemia (CML) is rare in the pediatric population, accounting for 2-3% of childhood leukemia cases, with an annual incidence of one case per million children. The low toxicity profile of imatinib mesylate has led to its approval as a front-line therapy in children for whom interferon treatment has failed or who have relapsed after allogeneic transplantation. We describe the positive responses of 2 children (case 1 - from a 7-year-old male since May 2005; case 2 - from a 5-year-old female since June 2006) with Philadelphia-positive chromosome CML treated with imatinib (300 mg/day, orally) for up to 28 months, as evaluated by morphological, cytogenetic, and molecular approaches. Our patients are alive, are in the chronic phase, and are in continuous morphological complete remission. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|